SUMMARY In two prospective studies of anticonvulsant therapy there was a high incidence of drug-induced skin reactions to phenytoin (7%) and carbamazepine (16.6%). High initial serum concentrations of these drugs appeared to be a factor influencing the occurrence of such skin reactions. 
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One of the commonest reasons for the early discontinuation of any drug is the development of drug induced erythematous skin reactions. This can present a particular problem with antiepileptic drugs such as phenytoin and carbamazepine where the early development of a skin eruption may 
Results
Sixty patients received phenytoin for epilepsy.
Exanthematous drug reactions occurred in five (8%). In one instance an exfoliative dermatitis developed which was associated with jaundice and abnormal liver function tests. Serum phenytoin levels were ascertained during the first month of treatment in three of these five patients (39-8, 21-2, and 1 8-4 ,ug/ml). One other patient who developed a skin eruption ten days after commencing phenytoin complained at that time of drowsiness and unsteadi-Serum anticonvulsant concentrations and the risk of drug induced skin eruptions Our findings suggest that it may be wise, wherever possible, to commence treatment with low doses of drug and to increase slowly the dose and serum level of carbamazepine and phenytoin in order to reduce the incidence of exanthematous drug eruptions. The possibility that dosage reduction, rather than drug withdrawal might be sufficient to control the exanthematous skin reaction has been suggested by others3 and might be considered in patients with less severe skin reactions.
The observations described here may also be of relevance to skin reactions related to other drugs. 
